- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Stephen Marmaras: Value and Co-Payment Assistance Programs
Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses value and patient co-payment assistance programs.
Transcript:
Are patient-assistance programs on the whole good or bad?
Well, we know that many of our community members rely on them to receive their therapy, so they’re very important. I think what is also important with patient-assistance programs is understanding that sometimes they can be abused. Our fear is that when they are abused, or when they’re used by individuals that may not actually need them, so to speak, it could compromise patient-assistance programs in general for the folks that are most vulnerable and need them.
I would point to a white paper that our organization did in collaboration with the University of Michigan [Center for Value-Based Insurance Design]. It looks at precision patient-assistance programs [and] how we can identify those vulnerable patients most at risk from a clinical standpoint and from a financial standpoint and making sure that co-pay assistance programs are available specifically to those individuals so that we can get people on the right treatment quickly.
I think it’s a balance. I think we need to be more responsible about applying co-pay assistance programs to individuals so that we can guarantee that they’ll be around for a longer period of time.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
